A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

February 26, 2024

Study Completion Date

February 26, 2024

Conditions
Malignant Rhabdoid Tumors (MRT)Rhabdoid Tumors of the Kidney (RTK)Atypical Teratoid Rhabdoid Tumors (ATRT)Selected Tumors With Rhabdoid FeaturesSynovial SarcomaINI1-negative TumorsMalignant Rhabdoid Tumor of OvaryRenal Medullary CarcinomaEpithelioid SarcomaPoorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)Any Solid Tumor With an EZH2 GOF Mutation
Interventions
DRUG

Tazemetostat

Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene

Trial Locations (32)

1000

Institut Jules Bordet Medical Oncology Clinic, Brussels

2050

Chris O'Brien Lifehouse, Camperdown

3000

University Hospital Leuven, Leuven

10002

National Taiwan University Hospital, Taipei

10065

Memorial Sloan Kettering Cancer Center, New York

13125

Sarcoma Center HELIOS Klinikum Berlin, Berlin

20133

Instituto Nazionale Tumori - National Cancer Institute Via Giacomo Venezian, Milan

32224

Mayo Clinic - Jacksonville, Jacksonville

33076

Institut Bergonie, Bordeaux

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

University of Michigan, Ann Arbor

60611

Northwestern Memorial Hospital, Chicago

63130

Washington University, St Louis

69008

Centre Leon Berard, Lyon

75248

Institut Curie, Paris

75651

Hospital Pitie Salpetriere, Paris

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Denver, Aurora

86156

Children's Hospital Augsburg Klinikum, Augsburg

94115

University of California San Francisco, San Francisco

94800

Institut Gustave Roussy, Villejuif

97239

Oregon Health Sciences University, Portland

98105

Seattle Children's Hospital, Seattle

98109

Fred Hutchinson Cancer Research Center, Seattle

02114

Massachusetts General Hospital - Cancer Center, Boston

02215

Dana Farber Cancer Institute, Boston

QLD 4102

Metro South Hospital and Health Service via Princess Alexandra Hospital, Woolloongabba

T6G 1Z2

Alberta Health Services, Edmonton

M5G 1X8

Princess Margaret Hospital, Toronto

H4A 3J1

McGill University Health Centre - Royal Victoria Hospital, Montreal

NW1 2PG

University College London Hospital, London

SW3 6JJ

Royal Marsden Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Epizyme, Inc.

INDUSTRY

NCT02601950 - A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter